Investigational drug · Phase 3
YL201
Also called: Tambotatug Pelitecan, Tam-Peli
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
14
Any phase or sponsor naming "YL201"
First trial start
2022
May 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YL201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Small Cell Lung Cancer
- Metastatic Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Esophageal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Advanced Solid Tumors
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "YL201" as an intervention, largest first.
- A Study YL201 in Patients With Selected Advanced Solid TumorsActive, not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT06057922 · 990 participants (planned) · Start Sep 22, 2023 · Primary completion Oct 2026
Drug: YL201 for Injection · For: Advanced Solid Tumor
Sites: Hefei, China; Beijing, China; Chongqing, China · 52 sites in all
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerPivotal-lookingRecruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07739758 · 442 participants (planned) · Start Aug 18, 2026 · Primary completion Jun 2029
Drug: YL201; Serplulimab and 2 more · For: SCLC, Extensive Stage
Sites: Guangzhou, China; Shenyang, China
- A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyPivotal-lookingRecruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07487896 · 440 participants (planned) · Start Mar 24, 2026 · Primary completion Apr 30, 2028
Drug: YL201; Paclitaxel and 2 more · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Anqing, China; Bengbu, China; Hefei, China · 81 sites in all
- A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)Pivotal-lookingActive, not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT06612151 · 438 participants (planned) · Start Dec 17, 2024 · Primary completion Dec 1, 2027
Drug: YL201; topotecan hydrochloride for injection · For: Small Cell Lung Cancer
Sites: Guangzhou, China
- A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)Pivotal-lookingActive, not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT06629597 · 400 participants (planned) · Start Dec 31, 2024 · Primary completion Dec 1, 2027
Drug: YL201; Docetaxel and 2 more · For: Nasopharyngeal Carcinoma
Sites: Guangzhou, China
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyPivotal-lookingNot yet recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07803783 · 320 participants (planned) · Start Oct 2026 · Primary completion Jan 2029
Drug: Tambotatug pelitecan; Liposomal irinotecan and 2 more · For: Metastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Shanghai, China
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT05434234 · 312 participants (planned) · Start May 25, 2022 · Primary completion Apr 6, 2027
Drug: YL201; YL201 and 1 more · For: Advanced Solid Tumor
Sites: Fair Oaks, California; La Jolla, California; Lone Tree, Colorado · 45 sites in all
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07208773 · 260 participants (planned) · Start Oct 29, 2025 · Primary completion Jan 2027
Drug: YL201; Ivonescimab · For: Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer
Sites: Guangzhou, China
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.Pivotal-lookingRecruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07258979 · 202 participants (planned) · Start Nov 5, 2025 · Primary completion Feb 2028
Drug: YL201; Toripalimab and 1 more · For: Recurrent or Metastatic Nasopharyngeal Carcinoma
Sites: Chongqing, China; Fuzhou, China; Xiamen, China · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin 6: Analysis of the Phase I/Ib Trial.
Hu J, Zhong X, Ma Y, et al. · Clin Cancer Res 2026
- Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.
· Cancer Discov 2026
- Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
Zhao Y, Liu H, Meng X, et al. · N Engl J Med 2026
- Tambotatug pelitecan - a potential new second-line treatment option for SCLC.
Killock D · Nat Rev Clin Oncol 2026
- Design, synthesis and evaluation of novel 1,3-benzodioxole derivatives for their anti-tumor activity.
Wang XJ, Wang BY, Zhang B, et al. · Fitoterapia 2025
- A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Ma Y, Yang Y, Huang Y, et al. · Nat Med 2025
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.